Alpha memo: resveratrol exercise protocol mismatch

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• Synthesis could explicitly note that Receipt 1 is feasibility/pilot without efficacy adjudication, which already implies non-additivity cannot be inferred from it alone.
• The phrase 'analogous cross-context signal rather than a direct flip' is slightly euphemistic; a one-line clarification that the two receipts should be read as convergent on null/attenuation rather than contradictory would tighten the bound.

Reviewer note

The memo satisfies the alpha-memo brief: one bounded research signal (resveratrol added to exercise may shift net effect from additive-leaning toward null or attenuated, direction sensitive to population, dose, and endpoint), built on two small but well-matched receipts. Receipt 1 (n=60, older adults with functional limitations, 500/1000 mg/day resveratrol + walking+resistance for 12 weeks) is correctly characterized as safety/feasibility-focused. Receipt 2 (n=27 aged men, 250 mg/day trans-resveratrol + HIIT for 8 weeks) is correctly read as showing blunted MAP improvement in the resveratrol arm. The memo accurately flags that Receipt 1 does not establish additive functional gain (consistent with the pilot framing in the excerpt) and that Receipt 2's attenuation claim applies to a cardiovascular endpoint, not physical function. Caveats/falsifiers enumerate the confounds (modality, dose, duration, sample size, endpoint family) and propose a decisive test RCT. Sources are recent enough, accurate to bundle entries, and directly support the bounded claim. The conclusion stays proportionate: context-dependent, not settled, no clinical/policy/investment prescriptions. Recommend accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis